FANGZHOU JIANKE (06086) has announced the successful completion of its placing, which was finalized on January 29, 2026, and the subsequent top-up subscription, which was settled on February 2, 2026. Under the terms of the placing and subscription agreement, a total of 45.181 million placing shares were successfully allocated by the placing agent to no fewer than six placees at a placing price of HK$3.32 per share.

Furthermore, as all conditions of the subscription have been satisfied, the company allotted and issued 45.181 million subscription shares (equivalent to the number of placing shares successfully placed) to the seller on February 2, 2026, at a price of HK$3.32 per subscription share. The subscription shares represent approximately 3.26% of the company's total issued share capital as enlarged by the allotment and issue of the new shares.

The net proceeds raised from the subscription amount to approximately HK$144.3 million. The company intends to allocate the net proceeds as follows: roughly 90% will be used to accelerate the development of its AI-driven chronic disease management platform, encompassing model development and optimization, infrastructure and computational resource expansion, recruitment of talent in AI and medical expertise, data acquisition, labeling, and knowledge base development, as well as the launch and promotion of AI-enhanced services to reach underserved patient and doctor populations; approximately 10% will be allocated for working capital and other general corporate purposes.